Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-hydroxystaurosporine
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
7-hydroxystaurosporine is a synthetic derivative of staurosporine with potent antineoplastic (anticancer) activity. It acts as a broad-spectrum protein kinase inhibitor, targeting multiple kinases including serine/threonine kinase AKT, calcium-dependent protein kinase C (PKC), cyclin-dependent kinases (CDKs), checkpoint kinase Chk1, and others. By inhibiting these kinases, it disrupts cell cycle progression—arresting tumor cells at the G1/S phase—and impairs DNA repair mechanisms by inhibiting the G2 checkpoint via Chk1 inhibition, ultimately leading to apoptosis. The drug has been investigated in clinical trials for various advanced solid tumors and hematologic malignancies[1][2][5][10].
- Other names
- 7-hydroxystaurosporine112953-11-4
02
Targets
PDK (Pyruvate dehydrogenase kinase isoform 1)AKT (RAC-alpha serine/threonine-protein kinase)CHEK1 (Checkpoint kinase 1)CHEK2 (Checkpoint kinase 2)CDK1 (Cyclin-dependent kinase 1)CDK2 (Cyclin-dependent kinase 2)CDK5 (Cyclin-dependent kinase 5)GSK3 (Glycogen synthase kinase 3 beta)LCK (Proto-oncogene tyrosine-protein kinase Lck)PKA (Cyclic amp-dependent protein kinase)PKC (Protein kinase C family)MAPK14 (p38 mitogen-activated protein kinase alpha)PRKCA (Protein kinase C alpha)PRKCB (Protein kinase C beta)PRKCD (Protein kinase C delta)PRKCG (Protein kinase C gamma)
Beyond the preview
Go deeper on 7-hydroxystaurosporine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7-hydroxystaurosporine.